This interventional trial (n=40) will evaluate the safety and effectiveness of hormone replacement therapy (HRT), magnetic resonance therapy (MeRT), ibogaine, and 5-MeO-DMT in treating post-traumatic stress disorder (PTSD) and cognitive difficulties in Special Operations Forces veterans with a history of combat deployment and traumatic brain injury (TBI).
Sponsored by the Special Operations Care Fund (SOC-F) and conducted by the Johns Hopkins Center for Psychedelic and Consciousness Research, this study will assign participants to two different sequences of interventions to assess their impact on PTSD symptoms and cognitive function.
Participants will undergo treatment with HRT, followed by either MeRT or ibogaine and 5-MeO-DMT, with self-reported surveys, cognitive assessments, and informant reports tracking changes. The primary outcome measures include PTSD symptom reduction, cognitive function improvement, and emotional memory processing. The study also aims to determine whether the order of treatments influences effectiveness. Findings from this trial may help guide future clinical trials and improve treatment options for veterans with severe, treatment-resistant PTSD and cognitive impairment.
Trial Details
Trial Number
Sponsors & Collaborators
Johns Hopkins UniversityJohns Hopkins University (Medicine) is host to the Center for Psychedelic and Consciousness Research, which is one of the leading research institutes into psychedelics. The center is led by Roland Griffiths and Matthew Johnson.